AFINITOR
FDA Approves Supplemental Application for Retevmo (Selpercatinib)
Pressure score
79
Momentum score
64
Why This Matters
Lilly is a regulatory competitive threat because recent agency-facing activity on AFINITOR in Oncology · mTOR Inhibitor may reset approval benchmarks and timeline expectations for Novartis.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Approved
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Approved competitor status elevates immediate revenue and share risk.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA Approves Supplemental Application for Retevmo (Selpercatinib)
Oncology · RET Inhibitor · Regulatory Approval · This approval enhances Eli Lilly's position in the oncology market, particularly in RET-altered cancers, potentially increasing competition against other RET inhibitors.
Source: Humanexa Signals
No public source document URL on file.
Related Signal
FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Lilly
1 competitive finding
Top program: AFINITOR
- Pressure
- 79
- Momentum
- 64
- Threat
- regulatory competitor
- Stage
- Approved
79LillyHighAFINITOR·Approved
Pfizer
1 competitive finding
Top program: AFINITOR
- Pressure
- 74
- Momentum
- 29
- Threat
- regulatory competitor
- Stage
- Approved
74PfizerHighAFINITOR·Approved